{
  "ticker": "JNJ",
  "target_date": "2025-03-26",
  "actual_date": "2025-03-26",
  "collected_at": "2025-12-08T11:33:50.559169",
  "price": {
    "open": 157.67,
    "high": 158.93,
    "low": 157.12,
    "close": 158.1727294921875,
    "volume": 7223500,
    "change_1d_pct": 0.43,
    "change_7d_pct": -0.69,
    "change_30d_pct": 4.41
  },
  "technicals": {
    "rsi_14": 34.99,
    "sma_20": 160.6,
    "sma_50": 153.77,
    "macd": 1.13,
    "macd_signal": 1.989,
    "macd_histogram": -0.859,
    "bb_upper": 164.19,
    "bb_lower": 157.01,
    "price_vs_sma20_pct": -1.51,
    "price_vs_sma50_pct": 2.87,
    "volume_ratio": 0.79
  },
  "fundamentals": {
    "market_cap": 489038708736,
    "pe_ratio": 19.592665,
    "forward_pe": 19.149055,
    "price_to_book": 6.160804,
    "price_to_sales": 5.307043,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.32,
    "pct_from_52w_low": 44.28
  },
  "macro": {
    "spy": {
      "price": 565.35,
      "change_1d_pct": -1.19,
      "change_7d_pct": 1.65
    },
    "vix": {
      "level": 18.33,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.34
    },
    "dollar_index": {
      "level": 104.55
    },
    "gold": {
      "price": 3020.9
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off",
      "source": "Yahoo",
      "datetime": 1743018011,
      "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about",
      "url": "https://finnhub.io/api/news?id=d1b87fd9d1607fcb0d7ebfd9c5dfb7bc04f5bd29a4bcf64b01c0fd8aeab54363"
    },
    {
      "headline": "Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",
      "source": "SeekingAlpha",
      "datetime": 1743012000,
      "summary": "The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.",
      "url": "https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636"
    },
    {
      "headline": "Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate",
      "source": "Yahoo",
      "datetime": 1743007049,
      "summary": "Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a",
      "url": "https://finnhub.io/api/news?id=fff9a4556ed0e684ae8bf06d03fb9d9a07dd44160c30f0e8c2c26f5686009485"
    },
    {
      "headline": "RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer",
      "source": "Yahoo",
      "datetime": 1743003900,
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT\u00ae (amivantamab-vmjw) plus LAZCLUZE\u2122 (lazertinib) significantly extended OS",
      "url": "https://finnhub.io/api/news?id=8338901da52e0f7881b5626f4504fc996e9cdf897d58f656d8d9eb808ae5dfb8"
    },
    {
      "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
      "source": "Yahoo",
      "datetime": 1742996410,
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=044da3b2d7cf3fd7d2abd605ab510c43cc86e0f5c03ee0dac248804e732ca3d4"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742429234.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000103/xslF345X05/wk-form4_1742429234.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}